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of modern China. Home to 79.6 million people, Jiangsu is one of the 
more prosperous provinces in the country with GDP per capita of 
$US12,000 (compared with $7,590 for all of China). Additionally, the 
province enjoys higher average life expectancy and lower maternal 
and infant mortality rates than the rest of the country. There is also a 
high level of urbanization of the population (66% in Jiangsu vs 55% 
for the rest of China). This is important as the prevalence of active 
TB in rural China is nearly double that of the urban population (307 
cases per 100,000 urban vs. 569 per 100,000 rural). There is also a high 
level of migration into the province, which introduces an estimated 
5,000 new TB patients each year.
Over the past decade TB control in Jiangsu province has out-
performed the wider Chinese community. Jiangsu province has 5% 
of the TB burden of China, with approximately 40,000 new patients 
every year. Since 2005 the number of TB notifications has noticeably 
decreased from 77 cases per 100,000 population to 42 cases per 
100,000 in 2014. In contrast, the number of notifications in China has 
decreased from 96 per 100 000 in 2005 to 65 per 100,000 in 2014. This 
is again welcome news in the global fight against TB and provides 
evidence that political commitment is essential for success. This 
commitment is now required to address MDR-TB.
Political Commitment
At a federal level, the management of TB lies with the National 
Health and Family Planning Commission. The Commission 
provides national leadership by establishing the “Guidelines for the 
implementation of tuberculosis prevention and treatment planning 
in China”. However, service delivery and cost recovery are delegated 
to the provinces. Funding for surveillance and treatment comes from 
three main sources, namely the provincial governments, individual 
patients and private medical insurers. The amount of funding 
contributed by the three parties is not controlled by the Commission, 
so individual provinces are left to devise policies to support service 
delivery. Jiangsu province has set the overall cost to MDR-TB patients 
at 10 – 30%, making out of pocket expenses one of the lowest in the 
country. This policy consideration is important as patients should not 
be discouraged from seeking clinical assistance for financial reasons.
In 2004 the Jiangsu provincial government established a co-
ordinate committee for the prevention and control of important 
infectious disease, which included TB and AIDS. The TB control 
project is reviewed by the Jiangsu provincial government every 5 
years. A network for TB control has been established that incorporates 
provincial, prefecture, county, township and village diagnostic and 
Introduction
Tuberculosis (TB) has been a major health problem for 
thousands of years [1-3]. It took almost 200 years after the discovery 
of the disease in early 1689 to identify the causative pathogen, namely 
Mycobacterium tuberculosis, by Robert Koch who was awarded a 
Nobel Prize in physiology or medicine in 1905 for his work in this 
area. Currently, TB is a global pandemic that outranks HIV-AIDS 
and malaria as the leading cause of death by infectious disease [4,5]. 
In 1993 the World Health Organization declared TB a global health 
emergency. At the turn of the centuary the United Nations set the 
ambitious Millennium Development Goal (MDG) of reducing the 
prevalence and mortality rates of TB to 50% of those observed in 
1990 by the 2015 deadline [6]. It can be argued that the policies and 
programs that were put into place have had an impact on TB control 
as the rates of new cases and mortality have reduced over the last 
decade to within reach of the 2015 target. In contrast, the prevalence 
of drug resistant infections is increasing [7]. Both single drug resistant 
TB and multidrug-resistant TB (MDR-TB) need to be addressed as a 
public health crisis in order to achieve the ambitious MDG target of 
complete elimination of TB as a public health concern by 2050 [4,7].
China is a key player in the global fight against TB. It is estimated 
that China has 1 million new cases of TB every year [8]. The overall 
disease burden is being controlled in China as the incidence has 
declined by 3.4% since 1990. The overall prevalence rate per 100,000 
population fell from 215 in 1990 to 108 in 2010 [8]. In 2010, China 
achieved its MDG for TB control 5 years ahead of the initial target 
date. This is indeed welcome news, and the authorities should be 
recognized for this significant achievement. However, the rise of 
multidrug resistant infections threatens to undo the good work of the 
past 25 years. It is estimated that 6.3% of the 1 million new cases of TB 
in China each year are now due to multidrug resistant tuberculosis 
(MDR-TB). MDR-TB infections are a major concern for healthcare 
providers, as they do not respond to front line antibiotics isoniazid 
and rifampicin. Instead these infections require more expensive and 
potentially more toxic second line drugs. These treatments often 
require extended courses of treatment with the associated cost. 
Whilst new shorter treatment regiments are available that substitute 
isoniazid with moxifloxacin, these have not been widely adopted in 
China as clinical efficacy has not been proven to be superior to the 
existing regimen.
Jiangsu Province
Jiangsu province in the south-east of the country is a microcosm 
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clinical agencies. A key objective is to strengthen the capabilities 
of the network by 1) enhancing human resource development, 2) 
increase the number of technical staff at all levels and 3) strengthen 
training at all levels with an emphasis on doctors in urban districts 
and rural townships.
Laboratory Network
An important resource in the fight against MDR-TB is the 
pathology laboratories that play essential roles in rapid diagnosis 
and TB surveillance. The data generated by these laboratories 
ultimately direct patient care and government policy. At the heart of 
the operation is the provincial laboratory run by the Department of 
Chronic Infectious Disease under the supervision of the Center for 
Disease Control and Prevention. The negative pressure laboratory 
is BSL-2 certified and has the capability to perform microbiological 
analysis such as TB sputum smear, culturing strain identification 
and drug susceptibility testing using the BACTEC™ MGIT™ 960 
Mycobacterial Detection System. It also has access to molecular 
detection techniques such as HAINs, GeneXpert and Genechip 
to detect drug-resistance markers in clinical isolates. These rapid 
molecular techniques can provide information for clinicians within 
hours and are faster than traditional microbiological techniques that 
require long culturing times. Under the provincial laboratory are 13 
prefecture TB laboratories, all of which have microbiological and 
molecular diagnostic capabilities. Also in the network are 73 county 
TB laboratories that all perform TB sputum smear and culturing 
assays, with 26 having molecular diagnostic capability. The aim here 
is to rapidly diagnose all TB patients and to prioritize those with 
MDR-TB.
Disease Reporting
An internet based Communicable Disease Reporting System 
has been established. This includes a TB management information 
system that stores individualized data of cases. The database has fast 
case searching and provides accurate statistic reporting. The data also 
facilitates timely assessment of government programmes.
DOTS-plus Strategy for MDR-TB
The WHO recommends the Directly Observed Treatment, 
Short-course (DOTS) strategy of policy, diagnosis, treatment and 
management of TB. DOTS is a five-point programme to: 1) secure 
political commitment and sustained funding;  2) ensure early case 
detection and diagnosis; 3) provide standardized treatment; 4) ensure 
effective drug stewardship and supply and 5) monitor and evaluate 
performance and impact. Management of MDR-TB is guided by 
DOTS-plus. DOTS-plus is developed on the basis of the DOTS 
strategy, but includes timely diagnosis and rational use of second-line 
anti TB drug treatment strategies. All suspected MDR-TB cases are 
confirmed by microbiology culture and molecular testing methods. 
Free MDR testing is also performed for five kinds of suspected patients, 
namely 1) chronic bacteria discharge/retreatment failure patients; 2) 
close contact to MDR patients with pulmonary tuberculosis of smear 
positive tuberculosis patients; 3) initial treatment failure patients; 4) 
recurrence and return patients and 5) smear positive patients after 
3 months treatment. All MDR-TB patients are treated by MDR-TB 
hospitals, are included in medical insurance policies and 70-90% of 
the medical fee can be claimed for reimbursement.
Key Challenges Ahead
As described earlier, initiatives to reduce TB burden are having 
an impact to drive down the global burden of TB. However, there 
will be a need for continued and diligent adherence to policies and 
revisions of goals in the decades to come. This will require ongoing 
political commitment to ensure sufficient and sustainable funding 
is available. Several imminent threats require ongoing monitoring 
and already place further strain on existing resources. The growing 
number of patients with HIV and those with TB - HIV co-infection 
are a significant concern. It is estimated that in 2011 China had 
13,000 HIV positive TB cases. Co-infected patients are treated 
with expensive multi-drug regiments, and for those with MDR-TB 
infection the number of drugs that can be administered becomes 
restrictive. Furthermore, migrants entering new communities that 
carry new TB strains are a continued threat. In Jiangsu, 5,000 new 
migrants harboring a TB infection enter the province each year. To 
maintain momentum in TB control authorities must improve the 
quality of DOTS and DOTS-plus implementation. TB control will 
also need to better integrate migrants and HIV patients. Jiangsu has 
proven itself ready to deal with the challenge and serves as a model 
for other countries with high TB burden. The province also highlights 
what can be achieved with sufficient resourcing and political will.
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